Path to the Clinic: Assessment of iPSC-Based Cell Therapies In Vivo in a Nonhuman Primate Model  by Hong, So Gun et al.
Cell Reports
ResourcePath to the Clinic: Assessment of iPSC-Based
Cell Therapies In Vivo in a Nonhuman Primate Model
So Gun Hong,1,5 ThomasWinkler,1,5 ChuanfengWu,1 Vicky Guo,1 Stefania Pittaluga,2 Alina Nicolae,2 Robert E. Donahue,1
Mark E. Metzger,1 Sandra D. Price,1 Naoya Uchida,3 Sergei A. Kuznetsov,4 Tina Kilts,4 Li Li,4 Pamela G. Robey,4
and Cynthia E. Dunbar1,*
1Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
3Molecular and Clinical Hematology Branch, National Heart Lung and Blood Institute-National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, Bethesda, MD 20892, USA





This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
Induced pluripotent stem cell (iPSC)-based cell
therapies have great potential for regenerative med-
icine but are also potentially associated with tumori-
genic risks. Current rodent models are not optimal
predictors of efficiency and safety for clinical appli-
cation. Therefore, we developed a clinically relevant
nonhuman primate model to assess the tumorigenic
potential and in vivo efficacy of both undifferentiated
and differentiated iPSCs in autologous settings
without immunosuppression. Undifferentiated autol-
ogous iPSCs indeed form mature teratomas in a
dose-dependent manner. However, tumor formation
is accompanied by an inflammatory reaction. On the
other hand, iPSC-derived mesodermal stromal-like
cells form new bone in vivo without any evidence of
teratoma formation. We therefore show in a large
animal model that closely resembles human physi-
ology that undifferentiated autologous iPSCs form
teratomas, and that iPSC-derived progenitor cells
can give rise to a functional tissue in vivo.
INTRODUCTION
The discovery of reprogramming methods able to generate
pluripotent cells from adult somatic tissues have stimulated
excitement that personalized cell-based regenerative medicine
therapies are within reach. Although many proof-of-principle
reports support the potential of using tissues produced from
induced pluripotent stem cells (iPSCs) for therapeutic pur-
poses, the actual feasibility and safety of these modalities
for human clinical applications remains controversial, given
very limited relevant preclinical data (de Almeida et al.,
2013; Kaneko and Yamanaka, 2013). Most in vivo models
for safety or efficacy have studied the behavior of murine
iPSC-derived cells in mice, or human iPSC-derived cells in1298 Cell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authorsprofoundly immunocompromised mice. Although murine
models may provide valuable proof-of-principle and mecha-
nistic information, murine physiology substantially differs
from the human setting, particularly in regard to the immune
and inflammatory systems (Seok et al., 2013). There appear
to be quite significant differences between murine and human
iPSCs or embryonic stem cells (ESCs) even when profiled
in vitro (Tesar et al., 2007). Human cells implanted in immuno-
deficient mice are unlikely to be able to integrate normally into
appropriate niches or assessed functionally, and any interac-
tion between human iPSCs and the immune system cannot
be addressed.
The teratoma assay has been the gold standard by which to
document pluripotency of human pluripotent stem cells (PSCs)
(Cunningham et al., 2012), but also assumes a preclinical impor-
tance to assess whether any pluripotent, tumorigenic cells
remain in the cell population following its differentiation into a
therapeutically relevant tissue of interest. Therefore, develop-
ment of an autologous preclinical teratoma model is desirable.
Recently, Zhao et al. reported that murine iPSCs were more
immunogenic than murine ESCs and could elicit T cell-mediated
immune responses against several teratoma proteins in
syngenic immunocompetent mice (Zhao et al., 2011). However,
two subsequent papers reported no immune rejection of murine
iPSC or their differentiated progeny tissues in syngenic mice
(Araki et al., 2013; Guha et al., 2013). These conflicting results,
in addition to the inherent limitations of rodent models for
modeling the physiology, safety, and efficacy of novel therapies,
have prompted us to develop a relevant large animal preclinical
model for iPSC therapies.
The rhesus macaque has been a very valuable model organ-
ism for development of novel cell and gene therapies, and
analysis of the immune system. Physiological similarity including
size and life span, phylogenetic similarity to humans, cross-reac-
tivity of human cytokines and antibodies, completed genome
sequencing, and knowledge gained from 3 decades of macaque
immunologic studies stimulated by the HIV epidemic contribute
to the utility of this model (Donahue and Dunbar, 2001; Lackner
and Veazey, 2007). Moreover, rhesus iPSCs resemble human
iPSCs in terms of morphology, marker expression, and growth
factor dependency to maintain their pluripotency (Liu et al.,
2008).
Bone regeneration is needed in case of critical bone defects
due to trauma, surgical resection of tumor, infection, aseptic
loosening of prosthetics, or nonunions (Steinert et al., 2012).
Bone marrow stromal cells (BMSCs), also termed mesen-
chymal stromal cells or mesenchymal stem cells (MSCs), can
be differentiated toward the osteogenic lineage and used to
create new osteoid matrices and new bone (Quarto et al.,
2001; Robey, 2011). Therefore, substantial research efforts in
the field of orthopedic regenerative medicine have been
devoted toward developing specific cell-based osteogenic
therapies using BMSCs. Although BMSCs can be isolated
from adult tissue, the procedure is invasive, expensive, and
laborious. Furthermore, adult BMSCs may have a limited
expansion capacity in vitro, especially when obtained from
aged donors and therefore may not be suitable to generate suf-
ficient therapeutic cells (Illich et al., 2011; Roobrouck et al.,
2008). iPSCs could serve as a virtually unlimited autologous
source of osteogenic precursor cells; in addition, genetically
corrected BMSCs can potentially be used for treatment of
genetic bone diseases. We target this mature tissue as a proof
of principle for autologous tissue regeneration from iPSCs in a
relevant large animal model.
RESULTS
Derivation of Transgene-free Rhesus iPSCs and
Adaptation to a Xeno-free Culture Surface
Rhesus iPSCs were generated via reprogramming of rhesus
BMSCs (RhBMSCs), skin fibroblasts, or CD34+ cells with the
excisable polycistronic lentiviral vector, STEMCCA, expressing
human POU5F1 (OCT4), SOX2, MYC, and KLF4 (Sommer
et al., 2010). Some rhesus dermal fibroblasts were transduced
with the inducible caspase-9 (iCasp9) suicide gene (Di Stasi
et al., 2011) before reprogramming. Rhesus iPSCs were
documented as pluripotent by morphology, gene expression,
in vitro differentiation, and teratoma formation in immune-
deficient NOD scid gamma c (NSG, NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) mice (Figure S1). The transgene cassettes
were excised by transient expression of Cre recombinase (Merl-
ing et al., 2013). Excision was confirmed by PCR (Figure 1A) and
Southern blot (data not shown). Five transgene-free rhesus
iPSCs (RhiPSCs) clones from two animals were selected for
further experiments (Table S1). These clones had normal and
stable karyotypes, with G-banding repeated just prior to
selected in vivo autologous implantation experiments. The
genomic location of the 303 bp nonexpressed proviral vector
fragment remaining in the genome following the transgene-
excision was mapped by a modified restriction enzyme-free
linear amplification-mediated polymerase chain reaction (Re-
free LAM-PCR) (Wu et al., 2013) in the RhiPSC clones to be
used for autologous transplantation (Table S1). The presence
of this inert DNA tag allowed unequivocal assessment of the
presence or absence of RhiPSCs following in vivo implantation.
Rhesus ESCs (RhESCs, ORMES-22) (Mitalipov et al., 2006) were
used as a positive control in all in vitro iPSC characterizationCsteps, including teratoma formation in immunodeficient mice
(Figure S1).
Transplantation of iPSCs or their progeny into an immunocom-
petent recipient in a clinical setting requires feeder-free, and
ideally, completely xenogeneic-free defined cell culture con-
ditions. We successfully adapted RhiPSCs to feeder-free
cultures using the widely used murine basement membrane
tumor extract, Matrigel, or Synthemax II-SC, a chemically
defined animal-free surface coating. Under these conditions,
the RhiPSCs retained ESC-like morphology, normal karyotype,
and their pluripotent phenotype as demonstrated by expression
of typical pluripotent markers such as OCT4, NANOG, SSEA4,
TRA-1-60, differentiation in vitro into embryoid bodies (EBs)
comprising the three embryonic germ layers, and teratoma
formation in NSG mice (Figures 1B–1K). Table S1 summarizes
characterization results for the five RhiPSC clones used in sub-
sequent in vivo and in vitro studies of teratoma formation and
differentiation.
Development of a Xeno-free Teratoma Assay
Extracellular matrix protein has been shown to greatly enhance
teratoma formation of PSC in the xenograft setting, particularly
with subcutaneous cell implantation approaches (Prokhorova
et al., 2009). Alternative injection methods such as intratesticu-
lar, intramuscular, or renal subcapsular injections are not prac-
tical and are too invasive to permit repeated harvesting in a
nonhuman primate transplant model. Use of subcutaneous in-
jection also permitted more injections per animal and allowed
continuous monitoring of mass size via calipers or ultrasound,
without repeated invasive procedures or prolonged anesthesia,
and permitted retrieval of the implants at various time points
for analysis, without danger to the animal. However, the most
commonly used supportive compound, Matrigel is composed
of proteins secreted by the murine Engelbreth-Holm-Swarm
sarcoma and is therefore likely to be highly immunogenic
following injection into an immune competent host such as the
rhesus macaque. We therefore tested alternative approaches
for teratoma assays in NSG mice. We hypothesized that use of
an autologous rhesus macaque three-dimensional matrix would
be most physiologic and relevant, and thus we tested if a rhesus
macaque plasma clot scaffold could be substituted for Matrigel
in teratoma assays.
The kinetics and quality of subcutaneous teratoma formation
in NSG mice from RhiPSCs suspended in a rhesus plasma clot
was comparable to those of teratoma formation in NSG mice
using Matrigel scaffold (Figure S2). The subcutaneous injection
of RhiPSCs suspended in IMDM medium alone, without any
three-dimensional matrix, was not sufficient to support teratoma
formation.
Autologous Teratoma Formation in the RhesusMacaque
Utilizing the plasma clot method, we tested whether or not
autologous iPSCs form teratomas in vivo in immunecompetent
rhesus macaques. A range of cell doses for three independent
Cre-mediated transgene excised autologous RhiPSC clones
(5 3 105–5 3 106 cells) were suspended in an autologous
clot and injected subcutaneously into the original #ZG15
donor macaque at a total of six sites (first teratoma assay).ell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authors 1299
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Figure 2. Autologous Teratoma Assay in
Rhesus Macaques
(A–D) All RhiPSCs in autologous plasma clots
formed teratomas in NSG mice. Histologically, the
tumors showed tissues derived from all three germ
cell layers (A, H&E 203) including immature (rare
foci) and mature neuroepithelial elements (B, H&E
2003), bone (C, H&E 2003) and cartilage (A), and
glandular structures (D, H&E 2003).
(E and F) In the first autologous rhesus macaque
experiment, one out of six implants of 1 3 105
RhiPSCs formed a well-defined 5 mm nodule, and
the mass was harvested at 10 weeks. On H&E
staining, dense, fibrous connective tissue with no
evidence of teratoma formation was observed (E,
H&E 203; F, H&E 4003).
(G and H) When 1 3 107 RhiPSCs were injected
autologously (second teratoma assay), an
immature teratoma developed 2 weeks post-
injection. The well-circumscribed nodule (G, H&E
203) showed proliferating immature neuro-
epithelial cells with scattered rosette formation
(H, H&E 4003).
(I–L) A mature teratoma developed by 10 weeks
after 1 3 107 RhiPSCs implantation, consisting of
mature glial tissue (I, H&E 203), squamous
epithelium (J, H&E 4003), well-vascularized
papillary choroid plexus structures (K, H&E 2003),
and well-differentiated glandular epithelium with
goblet cells (L, H&E 2003).
(M–P) The 30 week RhiPSCs-derived masses (M,
H&E 203, third teratoma assay) showed struc-
tures consistent with peripheral nerves (N,
H&E4003), choroid plexus (O, H&E 4003), and
mucinous epithelium (P, H&E 4003).
(Q) Growth kinetics of RhiPSC-derived mass size
per delivered cell number in autologous rhesus
macaques. Six 1 3 107 RhiPSC-derived masses
and three 2 3 107 masses were measured using
ultrasound every 7–10 days up to day 100. From
days 101 to 300, there were only two tumors
available for follow-up per each cell concentration.
Values represent mean ± SEM. See also Figures
S2 and S3.Concurrently, the same cells and clot preparations were in-
jected subcutaneously into NSG mice. In this initial experi-
ment, the RhiPSCs had been adapted to feeder-free growth
on Matrigel and were washed extensively to remove residual
Matrigel before suspension in plasma for injection. All animalsFigure 1. Feeder-free Culture of Transgene-free Rhesus iPSCs
(A) Transgene excision and silencing was documented by PCR and RT-PCR. (a,
(pre-excision)-derived SCs, p4 and p12, respectively; d, BMSCs.) Upper panel: M
(B–G) A long-term feeder-free culture of RhiPSCs was successful on both M
retained typical ESC morphology (B, 403; C, 1003) and expressed pluripotency
60 (G, 2003).
(H) RhiPSCs cultured on both Mat and Syn were able to differentiate into embryo
(I and J) They maintained normal karyotype (I) and were able to form teratomas
elements, cartilage, and neuroepithelial cells (J, hematoxylin and eosin [H&E] 403
II-SC-coated plates for 1 month.
(K) Differential expression of pluripotent and lineage specific genes following i
undifferentiated RhiPSCs. Values represent mean ± SEM. Mat EB and Syn EB rep
coated plates or Synthemax II-SC-coated plates, respectively. See also Figure S
Cwere closely monitored for teratoma formation, with up to
21 months of follow-up.
By 7 weeks, all NSG mice developed mature teratomas of
greater than 2 cm diameter (Figures 2A–2D). In contrast, only
one of six injection sites in the macaque had a palpable tumor,RhiPSC clone pre-excision; b, RhiPSC clone postexcision; c and c0, RhiPSC
YC/WPRE; lower panel: ACTIN.
atrigel-coated (Mat) and Synthemax II-SC-coated (Syn) plates. These cells
proteins, OCT4 (D, 2003), NANOG (E, 2003), SSEA-4 (F, 2003), and TRA-1-
id bodies (EBs) (403).
in NSG mice, with derivates from all three germ cell layers including glandular
). (B)–(J) show representative figures from clone M22-8 cultured on Synthemax
n vitro differentiation using EB method. Gene expression was normalized to
resent mRNA expression from EBs derived from RhiPSCs cultured onMatrigel-
1 and Table S1.
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Table 1. A Summary of Teratoma Formation Rates from RhiPSCs in Autologous Macaques and NSG Mice
RhiPSC No.
ZG15
ZG47 (4th assay) Rhesus Total NSG1st assay 2nd assay 3rd assay Total
5 3 105 0/2 0/1 — 0/3 0/2 0/5 2/2
2 3 106 0/3 — — 0/3 0/2 0/5 2/2
5 3 106 0/1 — — 0/1 — 0/1 —
1 3 107 — 2/3 1/1 3/4 1/6 4/10 3/3
2 3 107 — — 2/2 2/2 1/2 3/4 2/2
Tumors that were not harvested for PCR, qPCR, and histology analyses were not included in this table. See also Table S2.a small 2 mm nodule noted 8 weeks after injection (M22-8 iPSC,
5 3 105 cells injected). The nodule size increased to 5 mm by
week 9 but then stopped growing and was removed for analysis
at 10 weeks. Histologically, the nodule consisted of homoge-
nous, hypocellular fibrocollagenous tissue without evidence of
teratoma structures (Figures 2E and 2F). Although the RhiPSCs
were extensively washed to remove Matrigel prior to suspension
in autologous clot and implantation, we hypothesized that resid-
ual Matrigel may have triggered an immune response that
inhibited teratoma formation in the immune-competent auto-
logous rhesus macaque.
Therefore, as detailed above, we adapted RhiPSCs to culture
on the completely animal-free, synthetic surface Synthemax
II-SC, which had been previously determined not to elicit
systemic toxicity nor irritation in immune-competent animals
(tested by NAMSA). We performed the subsequent autologous
teratoma assays using Synthemax II-SC-cultured RhiPSCs
(second teratoma assay). We also increased the maximum
cell number implanted to 1 3 107 per site. Using cells
from ZG15, NSG mice again developed mature teratomas
whether low (5 3 105) or high (1 3 107) cell doses were im-
planted, but 5 3 105 RhiPSCs injected subcutaneously into
the autologous ZG15 rhesus macaque exhibited no tumor
growth for up to 15 months follow-up (Tables 1 and S2). In
contrast, ZG15 sites injected with 1 3 107 RhiPSCs developed
palpable masses with the first 7 days postinjection, and these
masses slowly increased in size and then plateaued within a
10 week observation period. Tumors were explanted serially at
2, 5, and 10 weeks. Masses harvested at 2 weeks contained
immature teratoma structures histologically, mainly consisting
of primitive neuroepithelial tissue (Figures 2G and 2H). At
5 weeks, we found fibromyxoid tissue with stellate mesen-
chymal cells and scattered capillaries, without evidence of ecto-
dermal or endodermal tissue differentiation (Figures S3A and
S3B), similar to the fibrous nodule explanted in the first experi-
ment. Samples harvested at 10 weeks had mature structures
derived from all three germ cell layers, histologically fulfilling
diagnostic criteria for a mature teratoma (Figures 2I–2L). Tera-
tomas persisted out to at least 30 weeks postinjection (third
teratoma assay, Figures 2M–2P). In a second animal, ZG47
(fourth teratoma assay), Synthemax II-SC-cultured autologous
RhiPSCs formed teratomas with similar kinetics to the first ani-
mal, at cell doses of 1–23 107 cells (Figures S3C–S3F). Howev-
er, sites injected with 53 105–23 106 cells did not show any tu-
mor growth. Results of all concurrent rhesus and NSG teratoma
assays are summarized in Tables 1 and S2. Figure 2Q summa-1302 Cell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authorsrizes the kinetics of growth for all RhiPSC-derived masses in
autologous rhesus macaques.
Conventional and quantitative PCR (qPCR) confirmed that all
explanted tissues were of RhiPSC origin, based on the pres-
ence of the residual vector DNA 303 bp tag, detected using
primers flanking the site of DNA tag insertion or directly target-
ing internal sequences within the DNA tag (Figure 3). Of note,
some tumors consisted only of fibromyxoid tissue and there-
fore did not fulfill the diagnostic criteria for teratomas (Figures
S3A and S3B and Table S2). In summary, we performed autol-
ogous teratoma assays using a total of 25 independent undif-
ferentiated iPSC implants in the monkeys, with concurrent
comparison to the same cells injected into immunodeficient
mice. Nine of nine implants at the cell doses used in this study
resulted in teratomas in NSG mice versus seven of 25 in rhesus
macaques (p = 0.0002 Fisher’s exact test), indicating that tera-
toma formation is less efficient in autologous monkeys than in
NSG mice.
Differentiation of RhiPSCs toward Mesodermal Stromal
Cells and Development of an Autologous Bone
Regeneration Model
Mesodermal stromal cells, also termed BMSCs, are defined
by adherent growth on plastic surfaces, typical fibroblastic
morphology, and the potential to form skeletal tissues, including
bone, cartilage, adipocytes, and hematopoiesis-supporting
stroma (Bianco et al., 2001, 2008). Functionally similar cells
derived from human iPSCs could potentially be used for tissue
replacement, in particular, for osteogenic diseases such as os-
teogenesis imperfecta (Robey, 2011). We investigated whether
RhiPSC-derived mesodermal stromal-like cells (RhiPSC-SCs)
could generate viable bone tissue in our autologous nonhuman
primate transplant model, in the absence of teratoma formation
or other adverse consequences. RhiPSCs were differentiated
in BMSC medium supplemented with platelet-derived growth
factor AB (PDGF), epidermal growth factor (EGF), and fibroblast
growth factor-basic (bFGF) (Figure 4A). Although the stromal-
like differentiation efficiency was comparable between RhiPSC
clones derived from various somatic cell sources such as fibro-
blasts, BMSCs or CD34+ cells, we observed some interclonal
variation in the efficiency of differentiation to cells with typical
connective tissue marker expression. Therefore, we enriched
for cells with a stromal-like phenotype via positive immunoselec-
tion for the cell surface MSC marker CD73, following 7–10 days
in a differentiation culture (Figure S4). This approach yielded
a phenotypically and morphologically homogenous
Figure 3. Molecular Analysis to Define the
Source of Tissue Masses
(A) PCR strategy to confirm that explanted tumors
originated from implanted RhiPSCs (M22-8) is
shown. Primers targeting either the residual DNA
tag (internal, 109 bp) or the genomic sequence
adjacent to the viral integration site (external) were
used.
(B and C) Representative insertion-specific PCR
utilizing external primers from ZG15 masses har-
vested at 10 weeks in the first teratoma assay (B)
andat 2, 5, and 10weeks in second teratomaassay
(C) are shown. The 271 bp band represents the
remaining wild-type allele of the chromosome 3
location and the 574 bp band corresponds to the
allele containing the residual vectorDNAsequence.
M, markers; BMSCs, bone marrow stromal cells;
M22, rhesus ZG15 iPSCs before excision; M22-8
iPSCs, transgene-free M22 iPSCs after excision;
Negative-1, excised tissue from site injected with
plasma clot alone; Negative-2, fat tissue sur-
rounding teratoma mass in ZG15; NSG, M22-8
iPSC-derived teratoma removed fromNSGmouse.
(D) Quantitative PCR with internal primers on tumors from first- and second-transplantation harvest after 2, 5, and 10 weeks confirm RhiPSC
origin of harvested tissue. Copy numbers are normalized to parental RhiPSC. Values represent mean ± SEM.population of cells very similar to primary RhBMSCs grown from
the bone marrow (Figure 4B), expressing the MSC markers
CD44, CD73, CD90, CD105, and CD166 (Figure 4C) but not plu-
ripotency genes (Figure 4D). These differentiated RhiPSC-SCs
but not parental RhiPSCs expressed MHC Class I (Figure 4E).
RhiPSC-SCs could be further differentiated toward the osteo-
genic lineage in vitro (Figure 4F) and did not form teratomas in
NSG mice followed up to 1 year (Table S3). We also derived
mesodermal stromal-like cells from RhESCs, and they were
similar to both RhBMSCs and RhiPSC-SCs in terms of gene
expression and MSC marker expression (Figure S5).
We initially tested the in vivo osteogenic differentiation
potential of autologous bone-marrow-derived RhBMSCs, to
document that the bone regeneration model utilizing non-
iPSC-derived primary cells was informative in primates. Rhesus
macaque primary BMSCs were grown from a marrow aspirate
and 2 3 106 cells were mixed with hydroxyl apatite/tricalcium
phosphate (HA/TCP) ceramic particles and implanted subcuta-
neously at multiple sites in the autologous macaque. The trans-
plants were retrieved at 8, 12, and 16 weeks later. Histologically
proven bone was formed as early as 8 weeks after implantation
(data not shown), similar in structure to bone formed using
human BMSCs implanted in immunodeficient mice at early
time points (Kuznetsov et al., 1997).
Four independent RhiPSC-SCs derived from the same
RhiPSC clones used for the teratoma assays were mixed with
HA/TCP particles and implanted subcutaneously at a total of
five sites in the autologous macaques. Concurrently, primary
autologous RhBMSCs were implanted as comparators, as
well as HA/TCP alone, without cell seeding. All grafts derived
from RhiPSC-SCs showed robust bone formation at 8 weeks
regardless of their RhiPSC origin, such as fibroblasts, BMSCs
or CD34+ cells. Histologically, the structures resembled bone
tissue derived from RhBMSCs (Figure 5). No bone formation
was observed with HA/TCP particles alone. Importantly, noCteratoma structures were observed in RhiPSC-SC implants.
To investigate whether detectable residual teratoma or tumor-
forming cells persist in the differentiated RhiPSC-SC implants
and whether bone formation was stable over time, we har-
vested three independent RhiPSC-SC-derived implants at later
time points (27–39 weeks). Again, the implants exhibit robust
bone formation with no evidence of teratoma formation
(Figure 5).
Characterization of Inflammatory Infiltrates in
Autologous Implants
Masses arising from implantation of undifferentiated autologous
RhiPSCs of ZG15 and ZG47 showed marked infiltration of
inflammatory cells, whereas those cells were absent in the
teratomas forming when the same cells were injected into im-
mune-deficient NSG mice. Immunohistochemistry showed
mixed B- and T-lymphocytic aggregates, mainly located in the
surrounding adipose tissue with some CD4+ and CD8+ lympho-
cytes scattered within the tumors (Figure 6). Additionally, eosin-
ophils infiltrated the immature teratoma harvested at 2 weeks
(Figure 6A). In the organized follicles with germinal centers, as
well as a few well-formed granulomas consisting of epithelioid
histiocytes admixed with multinucleated giant cells, dominated
the inflammatory infiltrates (Figure 6B).
In both autologous BMSC and RhiPSC-SC-derived implants,
other than foreign-body giant cells reflecting phagocytized HA/
TCP particles, very few small clusters of lymphocytes were
present up to 39 weeks of follow-up (Figure S6). Therefore,
the cellular inflammatory response was stronger following the
implantation of undifferentiated RhiPSCs as compared to the
differentiated cell grafts derived from the same RhiPSC clones.
Moreover, sites injected with autologous plasma clots with no
cells or RhiPSC-SCs, or autologous fibroblasts cultured on Syn-
themax II-SC in RhiPSCs culture medium and suspended in
autologous clot did not evoke inflammation nor tumor formation.ell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authors 1303
Figure 4. Mesodermal Stromal-like Cells
Differentiated from RhiPSCs
(A) Schema for the culture and enrichment steps
for RhiPSC-SCs derivation.
(B and C) After 4–6 weeks, RhiPSC-SCs show
typical BMSC morphology (B) and express
appropriate phenotypic markers as assessed
by flow cytometry, comparable to primary
RhBMSCs (C).
(D) After differentiation of RhiPSCs toward the
mesodermal lineage, pluripotency gene expres-
sion was downregulated, as assessed by qPCR.
Gene expression was normalized to undifferenti-
ated RhiPSCs. Values represent mean ± SEM.
(E) MHC class I expression was absent on
RhiPSCs and upregulated following differentiation
to RhiPSC-SCs, with CD73 used as a marker of
differentiation toward the mesodermal lineage.
(F) RhiPSC-SCs could be differentiated to osteo-
genic cells in vitro as demonstrated by alkaline
phosphate staining (403).
(B)–(F) are from a single representative data set.
See also Figures S4 and S5 and Table S3.To investigate whether there is an association between resid-
ual endogenous pluripotency gene expression and immuno-
genicity, immunostaining for OCT4 was performed on tumor
masses. No OCT4-positive cells were detected in any auto-
logous teratoma (Figure S7). To investigate whether the inflam-
matory response persists or has ablated in teratoma tissues
over time, masses from the ZG15 monkey were harvested at1304 Cell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authors30 weeks following implantation. Inter-
estingly, the inflammatory cell collections
were still present; however, the teratoma
structures remained intact, without evi-
dence for significant tissue damage (Fig-
ure 6C). Moreover, plasma cells were pre-
sent, suggesting chronic inflammation.
DISCUSSION
This study reports the parallel assess-
ment of the tumorigenic potential of un-
differentiated iPSCs and the regenerative
capacity of iPSC-derived somatic cells in
a clinically relevant immune competent
model. The risk of residual pluripotent
cells forming teratomas or other tumors
following transplantation of the tissues
derived from iPSC-derived cells is a
major concern impacting on future thera-
peutic applications of iPSC-derived
differentiated cells. Strategies to reduce
the risk by optimizing differentiation pro-
cedures, identifying new PSC-specific
selection markers (Tang et al., 2011), in-
hibitors (Ben-David et al., 2013), or sui-
cide ablation (Zhong et al., 2011) arecurrently under investigation but require a relevant physiologic
model. In particular, preclinical models allowing assessment of
the risks associated with the use of autologous iPSC-derived
cells in the presence of an intact immune system are critical.
Recent conflicting studies regarding the possible immunoge-
nicity of iPSCs or their differentiated progeny have generated
intense interest and require further investigation of this issue in
Figure 5. In Vivo Bone Formation from RhiPSCs
RhiPSC-SCs or RhBMSCs mixed with HA/TCP were implanted subcutane-
ously into the autologous donor animal and harvested at different time points
as late as 27–39 weeks postimplantation. H&E-stained slides were analyzed
either under bright field, polarized, or ultraviolet light. Multiple foci of new bone
formation were present in RhiPSC-SC implants. (A) shows bone in animal
ZG15 derived from iPSC cloneM11-10 RhiPSC-SCs; (B) shows bone in animal
ZG47 derived from iPSC clone H11-4 RhiPSC-SCs, and (C) shows bone in
animal ZG15 derived fromBMSCs. The irregular bone trabeculaewere rimmed
by osteoblasts and showed scattered osteocytes. Under polarized light,
collagen bundles were observed in bone matrix, organized in parallel patterns
consistent with the lamellar structure of new bone. Under ultraviolet light, new
bone demonstrated intense green fluorescence consistent with highly miner-
alized bone matrix. Long-term follow-up (27–39 weeks) of RhiPSC-SC im-
plants demonstrated stable bone formation with no evidence of teratoma
formation even this late. b, bone; v, vehicle. Images were taken at 2003.
Ca model with real relevance to the administration of autologous
or HLA-matched human iPSC-derived cells to patients (Araki
et al., 2013; Guha et al., 2013; Zhao et al., 2011). Undoubtedly,
murinemodels are valuable proof-of-principle tools for biological
and medical research but also have major limitations in predict-
ing more complex physiological processes involving the immune
system (Seok et al., 2013) or integration of transplanted cells into
functional organs. Furthermore, it is not clear if the phenotypes of
murine iPSCs and the molecular pathways maintaining self-
renewal are equivalent to those of human or nonhuman primate
counterparts (Okita and Yamanaka, 2006; Rao, 2004; Schnerch
et al., 2010).
Because of their physiological similarities to humans,
nonhuman primates can serve as a valuable translational
research model in moving toward early phase clinical trials in
humans. Modeling of all steps in iPSCs derivation, characteriza-
tion, differentiation, and autologous delivery can be accessed via
this model. The macaque immune system has been well charac-
terized due to the utility of macaques as models for HIV/AIDS
and is highly predictive of the human immune response (Picker
et al., 2012). The size and prolonged life expectancy of ma-
caques allow relevant long-term observation with repeated sam-
pling of administered iPSC-derived cells, very difficult in murine
models or in a clinical setting. Recently, Emborg et al. reported
that autologous rhesus iPSC-derived neuronal cells transplanted
intracerebrally showed engraftment ability as well as lack of
lymphocyte infiltration (Emborg et al., 2013). However, the
CNS is an immunologically protected and unique environment.
Therefore, there is still a question about immunogenicity and
tumorigenicity of iPSCs and their differentiated derivates when
they are grafted into immunocompetent sites (Lee et al., 2013;
Tang et al., 2013). Hence, there is a need to assess the safety
and efficiency of iPSC-based therapies in a clinically relevant
model (Kaneko and Yamanaka, 2013). To our knowledge, there
is no prior report of a teratoma assay in a large animal model
or a concurrent teratoma and differentiated tissue analysis.
In this study, we developed an autologous teratoma formation
assay in the rhesus macaque, following a long process of optimi-
zation in vitro and in vivo, removing xenogeneic components such
as Matrigel from the culture surface and implantation scaffolds
because it will likely trigger rejection of the RhiPSCs or their prog-
eny in an immunocompetent organism. Removal of xenogeneic
components is also highly desirable froma regulatory standpoint.
We found that theMatrigel scaffold could be replacedby anautol-
ogous plasma clot to reaggregate and support RhiPSCs im-
planted in vivo, as shown previously for implanted neural cells
(Lindsay et al., 1987). Besides the three-dimensional scaffold
function, plasma may also support teratoma formation by
providing growth factors stimulating both iPSCs themselves, as
well as angiogenesis required for teratoma or other new tissue
growth. Using this assay, we were able to show that undifferenti-
ated iPSCscan indeed formteratomas in vivo. Thismethod is sim-
pleandnoninvasiveandcanbeused fora varietyof applications in
the investigation and clinical development of tissue regenerative
therapies. Up to 30 sites can be injected and harvested in a single
macaque, without evident discomfort or clinical complications.
In this context, it is noteworthy that although the autologous
RhiPSCs did form mature teratomas in the macaques, theell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authors 1305
Figure 6. Inflammatory Reactions at
RhiPSCs Autologous Rhesus Macaque
Injection Sites
(A) Inflammatory reactions at 2 weeks in the sec-
ond teratoma assay. The mass shows multiple
lymphoid aggregates in the surrounding adipose
tissue (left panel) together with numerous eosino-
phils (detail inset 1,0003). The arrow in the original
picture indicates the location of the detail inset.
Immunostaining shows bothCD20-positive B cells
(middle panel, detail inset 4003) and CD3-positive
T cells (right panel). Among T cells, CD4-positive
cells and a few CD8-positive cells were present. A
few scattered CD56-positive NK cells are also
found. High-power pictures of CD3, CD4, CD8,
and CD56 are shown in insets of CD3 (all 4003).
(B) Inflammatory reactions at 10 weeks in the
second teratoma assay. The 10 week teratoma
was associated with granulomas consisting of
epithelioid histiocytes admixed with multinucle-
ated giant cells (left panel, 2003) as well as mature
lymphoid follicles with well-formed germinal cen-
ters (middle panel, 2003). Immunostaining of the
germinal center with CD20, CD3, CD4, and CD8 is
shown in (B), right panel (all 2003).
(C) Inflammatory reactions in the long-term tera-
toma tissue (30 weeks in the third teratoma assay). Multiple lymphoid aggregates were still present in the teratoma tissue up to 30 weeks after injection of
autologousRhiPSCs (left panel). In the follicles, bothCD20-positive B cells (middle panel, detail inset 4003) andCD3-positive T cells (right panel) were present. On
highpower, T cells are seen scattered throughout themass (insets, right panel, 4003). All imagesareH&E, and themagnification is 203unlessotherwise indicated.
See also Figures S6 and S7.process was at least 20-fold less efficient on a per cell basis
compared to teratoma formation following simultaneous injec-
tion of the same cells into NSG mice. The reduced tumor growth
could be hypothesized to be due to a less hospitable micro-
environment at rhesus versus murine injection sites based on
vascular supply or other factors; however, one would perhaps
expect that in the homologous species factors such as cytokines
would bemore favorable for the growth of RhiPSCs in amacaque
as compared to amouse. However, themore likely issue is the in-
fluence of an intact immune systemand inflammatory responses.
All the teratomas and masses that did result from implantation of
autologous RhiPSCs grew more slowly than in NSG mice and
seemed to plateau in growth after several weeks, correlating
with development of a significant inflammatory infiltrate sur-
rounding the ectopic tissues. None of the cells implanted in
NSG mice ever presented with a similar infiltrate, making it un-
likely that these lymphoid and myeloid cells originated from the
RhiPSCs themselves, although we cannot formally exclude that
possibility given that perhaps the murine environment may not
support rhesus lymphopoiesis, and development of human he-
matopoietic cells from human iPSCs within teratomas grown in
immunodeficient mice has been reported, albeit only with coin-
jection of stromal cells optimized for support of hematopoiesis
(Amabile et al., 2013). All RhiPSC lineswere karyotypically normal
when they were transplanted into the autologous animal,
although development of a ‘‘neoantigen’’ via mutation cannot
be ruled out. Sites injected with matrix but without cells, with
autologous fibroblasts in matrix, or with RhiPSC-SCs derived
from the same iPSC clones in either a plasma clot or a ceramic
matrix for the bone formation assays did not show similar inflam-
matory reactions or immune cell infiltration.1306 Cell Reports 7, 1298–1309, May 22, 2014 ª2014 The AuthorsIn this study, we transplanted undifferentiated RhiPSCs and
differentiated cells derived from the same RhiPSC clones in
the same recipient. We observed significant lymphocytic infil-
trations in teratoma tissues derived from undifferentiated
RhiPSCs, whereas no evidence of lymphocytic infiltrations in
bone tissues derived from RhiPSC-SCs. Although previous
studies using murine models resulted in conflicting conclusions
on the difference of immunogenicity between undifferentiated
ESCs and iPSCs, they all described some but various levels
of immune responses in teratoma tissues derived from syngenic
undifferentiated iPSCs (Araki et al., 2013; Guha et al., 2013;
Zhao et al., 2011). Guha et al. observed some lymphocytic infil-
trates in teratoma tissues derived from syngenic murine iPSCs
and ESCs, but not in in vivo grafts derived from their differenti-
ated counterparts (Guha et al., 2013), which is similar to our
results. However, BMSCs potentially have potent anti-inflam-
matory capabilities (Atoui and Chiu, 2012; Nasef et al., 2008),
and therefore reduced inflammation in the bone assay may
reflect anti-inflammatory properties of the specific injected
iPSC-SCs and may not be generalizable. It is interesting to
consider that mixing iPSC-SCs with other iPSC-derived tissues
might prevent inflammation and rejection following transplanta-
tion of therapeutic tissue grafts. On the other hand, autologous
skin fibroblasts cultured in iPSC culture medium as well as on
Synthemax II-SC plates did not result in inflammation. There-
fore, it seems to be likely that the inflammatory response in
the iPSC-derived teratoma tissues is directed against cellular
components. Further study will be needed to investigate
whether undifferentiated iPSCs and/or tissues derived from
them were directly associated with inflammatory reactions
observed.
This phenomenon might be due to residual pluripotent gene
expression in the tumors derived from autologous iPSCs, as
described (Dhodapkar et al., 2010; Tang et al., 2013). However,
we did not detect residual OCT4 expression in teratoma tissues
despite ongoing lymphocytic infiltration. It is also possible that
NK-mediated rejection of PSCs but not of differentiated cells
occurred due to low MHC class I expression on PSCs (Atoui
and Chiu, 2012; Tang et al., 2013). In this study, we also
found that MHC class I was not expressed on undifferentiated
RhiPSCs, but was re-expressed during differentiation to
RhiPSC-SCs. However, we did not actually detect any signifi-
cant NK infiltrate in or around the teratomas or fibrous nodules
in the autologous macaques, with only a few CD56-positive cells
at 2, 5, 10, or 30 weeks. One prior study actually noted a more
significant inflammatory response and T cell infiltration after
injection of murine iPSCs that did not have full pluripotency in
a blastocyst injection assay, suggesting there might be a link
between less than complete pluripotency and immunogenicity
(Araki et al., 2013). The five clones we used in this study fulfilled
all criteria for pluripotency except generating chimeric animals,
which is not feasible to perform conventionally in a nonhuman
primate model. Also, bone tissues derived from implantation of
iPSC-derived stromal cells generated from the same iPSC
clones did not exhibited significant T cell infiltration. Further
study will be needed to define more specific immune cell types
in teratomas, via phenotypic and functional analyses.
iPSC-derived SCs seem to be promising for musculoskeletal
regeneration. Potentially, iPSC-SCs can also be used for a vari-
ety of other clinical applications including immunomodulation.
Recently, derivation of mesenchymal-like precursors and/or
subsequent osteoblast lineage cells from human PSCs has
been reported (Kuznetsov et al., 2011; Lian et al., 2010; Marolt
et al., 2012; Vodyanik et al., 2010). Villa-Diaz et al. showed that
human iPSC-derived osteogenic cells contributed to de novo
bone formation in calvarial defects produced in immunodeficient
mice (Villa-Diaz et al., 2012). Bilousova et al. recently showed
that iPSC-derived osteoblasts are able to form bone in syngenic
mice (Bilousova et al., 2011). In our model, RhiPSC-SCs
morphologically resembled BMSCs, expressed similar cell
surface markers, and differentiated down the osteogenic lineage
in vitro. However, in vitro osteogenic differentiation from BMSCs
has not been a reliable predictor for the functionality of these
cells in vivo (Robey, 2011). The heterotopic bone formation
assay has been used as a gold standard to investigate the in vivo
bone formation ability of human or mouse BMSCs in SCID mice
(Kuznetsov et al., 2011; Marolt et al., 2012). In order to circum-
vent the long term in vitro osteoblast differentiation procedure,
we show that RhiPSC-SCs can directly contribute to bone for-
mation in vivo.We showhere that these cells are functional in vivo
in a clinically relevant autologous setting. One can simulta-
neously test multiple potential therapeutic cell lines or carriers
with a minimum number of animals. Moreover, this assay can
be performed simultaneously with a teratoma assay, which
allows direct comparison of undifferentiated RhiPSCs and their
differentiated progeny in terms of in vivo safety and function.
Using this platform, we showed that RhiPS-SCs can produce
mineralized bone in vivo. Importantly, in contrast to previous
reports using bone differentiation-induced pluripotent cells inCmouse models (Hayashi et al., 2012; Kuznetsov et al., 2011),
we did not observe any teratoma structures in the tissues
derived from RhiPSC-SCs.
In conclusion, by creating and functionally testing iPSC-
derived cells in vivo, our model accelerates the potential of
iPSC-based cellular therapies. The fact that none of the
RhiPSC-SC implants showed any signs of tumor formation,
and the low efficiency of teratomas derived from parental iPSCs
indicates that the risk of these adverse events is calculable and
probably can be further reduced by improved differentiation
methods or safety switches such as suicide-gene technology.
In summary, we believe that the presented nonhuman primate




All animals used in this study were housed and handled in accordance with
protocols approved by the Animal Care and Use Committee of the National
Heart, Lung and Blood Institute (H-0255 and H-0084).
Generation of Rhesus iPSCs
Rhesusmacaque (Macacamulatta) dermal fibroblasts, BMSCs, or CD34+ cells
were transduced once with a polycistronic lentiviral vector encoding the four
reprogramming factors OCT4, SOX2, KLF4, and MYC flanked by loxP sites
(Sommer et al., 2010). After 4–5 days, transduced cells were transferred to
plates coated with mouse embryonic fibroblasts (MEF) and cultured in 5%
oxygen in RhiPSCs medium (KO/DMEM [Gibco, Life Technologies]) supple-
mented with 20% knockout serum replacement [Life Technologies],
20 ng/ml human bFGF [PeproTech], 0.1 mM MEM nonessential amino acids
[Life Technologies], 1% penicillin-streptomycin-glutamine [PSG, Life Technol-
ogies], and 0.1mM2-mercaptoethanol [Sigma-Aldrich]). Between days 14 and
30, morphologically ESC-like colonies were mechanically selected, trans-
ferred to new MEF-coated plates, and mechanically passaged every 4–
5 days. Matrigel (BD Biosciences) and Synthemax II-SC (Corning)-coated
plates were prepared according to manufacturers’ protocols. Clones
confirmed to be pluripotent, as described below, were adapted to growth on
Matrigel or Synthemax II-SC-coated plates and cultured at least 3 months
without obvious phenotypical alterations. Cells were cryopreserved in ES-
defined FBS (HyClone) supplementedwith 10%DMSO (Sigma-Aldrich). A rhe-
sus macaque ESC line (ORMES-22, a gift from Dr. Shoukhrat Mitalipov) was
cultured as described previously (Mitalipov et al., 2006).
Cre-Mediated Transgene Excision
RhiPSCs were cultured on Matrigel-coated 12-well plates in MEF-conditioned
medium supplemented with 10 mM Rock inhibitor (STEMCELL Technologies).
The following day, a Cre-GFP-puro plasmid (kind gift from Dr. Harry L. Malech)
was transfected into the RhiPSCs using Lipofectamine LTX (Invitrogen, Life
Technologies) (Merling et al., 2013). Selection was performed with 2–3 mg/ml
puromycin for 3 days. MEF feeder cells were added, and medium was
changed to RhiPSCs culture medium until the RhiPSCs formed colonies.
Removal of the loxP-flanked STEMCCA-loxP vector was confirmed by trans-
gene PCR and copy number qPCR. For further details, please refer to Supple-
mental Experimental Procedures.
Immunohistochemistry for Pluripotency Markers
Cells were fixed with 4% paraformaldehyde at room temperature for 20 min
and blocked with 10% goat or donkey serum (Jackson ImmunoResearch
Laboratories). For cytoplasmic protein staining, 0.1% Triton X-100 was added
for permeabilization. Primary antibodies were then added and incubated at
4C overnight. Cells were washed and exposed to secondary antibodies
conjugated with fluorochromes before costaining with DAPI. All antibodies
are listed in Table S4.ell Reports 7, 1298–1309, May 22, 2014 ª2014 The Authors 1307
Teratoma Assay in NSG Mice
Female or male immunodeficient NSG mice aged 4–8 weeks were used.
Undifferentiated RhiPSCs were harvested, mixed with Matrigel in a 1:1 ratio,
or suspended in a rhesus plasma clot (see below) and injected in a volume
of 200–300 ml subcutaneously or 100 ml intramuscularly. Mice with tumors
with an approximate diameter of 2 cmwere euthanized and the excised tumors
were fixed in Bouin’s solution (Sigma-Aldrich).
SC Differentiation from RhiPSCs
Our differentiation protocol for RhiPSCs toward mesodermal stromal-like cells
was adopted and modified from a previous report utilizing human iPSCs (Lian
et al., 2010). Briefly, RhiPSCs were cultured on MEF or Matrigel. Undifferenti-
ated RhiPSCs at day 5 were dissociated using Accutase (STEMCELL Technol-
ogies), and, if MEF were present, they were removed using magnetic activated
cell sorting (Feeder removal kit, Miltenyi Biotec). Cells were transferred onto
gelatin-coated plates in BMSC culture medium (a-MEM [Life Technologies],
20% non-heat-inactivated fetal bovine serum [Atlanta Biologicals], and 1%
PSG) (Kuznetsov et al., 1997) supplemented with 10 ng/ml bFGF, 10 ng/ml
PDGF, and 10 ng/ml EGF, all from PeproTech. After 7–10 days culture, cells
were stained with anti-CD73-PE (BD Biosciences) and enriched for CD73-
expressing cells using anti-PE magnetic beads (Miltenyi Biotec). Flow cyto-
metric analysis was performed for the following surface antigens: CD44,
CD73, CD90, CD105, CD166, CD34, and CD45 (sources listed in Table S4).
For osteogenic differentiation, RhiPSC-SCs were plated at 45,000 cells per
35 mm dish. At 70%–80% confluency, the medium was switched to Stem-
MACS OsteoDiff Medium (Miltenyi Biotec) and changed every 3 days. After
10–14 days, cells were fixed and stained for alkaline phosphates using the
SIGMAFAST BCIP/NBT kit (Sigma-Aldrich).
Rhesus Cell In Vivo Transplantation
All procedures were performed under general anesthesia. For teratoma
assays, RhiPSCs (5 3 105–2 3 107) were suspended in 270 ml autologous
plasma separated from rhesus whole blood anticoagulated with buffered
sodium citrate at a final concentration of 0.129 M (BD Biosciences). Clot for-
mation was initiated by addition of CaCl2 to a final concentration of 3 mM,
and the solution was immediately injected subcutaneously using 20 gauge
needles. For in vivo bone formation assays, a 1–2 cm skin incision was
made to create a subcutaneous pocket and an aliquot of 40mg sterile HA/TCP
scaffold ceramic powder (0.5–1.0 mm in diameter, Zimmer) mixed with 23 106
autologous RhiPSC-SCs or RhBMSCs was placed in the pocket using a sterile
spatula. The incision was closed, and the location of each injection site or bone
formation pocket was marked on the skin with a permanent tattoo. Injection
sites were assessed in anesthetized animals manually and by ultrasound
at least weekly, measured with calipers, and harvested at defined time points.
Teratomas were fixed with Bouin’s solution and processed for immuno-
histologic and morphologic analyses. HA/TCP bone explants were fixed,
decalcified, processed for histology, and analyzed as previously described
(Kuznetsov et al., 2011).
Histological Analyses of Tissue Grafts
Immunohistochemistry studies were performed on 3 mm fixed, paraffin-
embedded or frozen tissue sections. The dewaxed and rehydrated slides
were subjected to antigen retrieval, consisting of 20 min high temperature
heating in PT Link (Dako) in either high pH solution (Dako) for CD3 slides or
low pH solution (Dako) for CD20 slides. A microwave retrieval method using
a pressure cooker with either 10 mM Citrate buffer (pH 6.0) (K.D. Medical) or
0.5mMEDTA (pH 8.0) (Quality Biological) was used for CD4 andCD56, respec-
tively. Next, 15 min blocking with 3% Tris goat serum and then incubation with
primary antibodieswas performed. For detection, the EnVision FLEXmouse kit
(Dako) was used for CD3, CD4, and CD20, and the Ultra-View DAB detection
kit (VentanaMedical Systems) was used for CD56. Human tonsil sections were
included as positive controls for antibody staining. CD8 staining was per-
formed in New England Primate Research Center in Harvard Medical School.
Briefly, slides were baked at 60C, and then a pressure cooker with Trilogy so-
lution (Cell MarqueCA) and Dual Endogenous Enzyme Blocking Reagent
(Dako) was used for antigen retrieval and blocking procedures, respectively.
For detection, EnVisionTM Dual Link System-HRP kit (Dako) was used.1308 Cell Reports 7, 1298–1309, May 22, 2014 ª2014 The AuthorsOCT4 staining was performed according to manufacturers’ protocols. The
detailed information of antibodies used in this study is listed in Table S4.
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